What do systematic reviews say?

Recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu) plus transarterial chemoembolisation vs chemoembolisation

The review found no eligible studies for this question.

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

E1B‐deleted (dl1520) adenovirus vs percutaneous alcohol injection

The review found no eligible studies for this question.

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) vs hydroxycamptothecin

It is very uncertain whether recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) changes overall survival Censored compared with hydroxycamptothecin (very low certainty).

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  RR 3.06 [0.16, 60.47]
  1 study · 48 participants
  Very low

Adjuvant S‐1 vs gemcitabine

It is very uncertain whether adjuvant S‐1 changes all‐cause mortality: 1‐year overall survival compared with gemcitabine (very low certainty).

• Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma 2021 · Cochrane Headline outcomes only
  RR 0.38 [0.15, 0.96]
  1 study · 70 participants
  Very low

Adjuvant S‐1 vs gemcitabine

It is very uncertain whether adjuvant S‐1 changes all‐cause mortality: 2‐year overall survival compared with gemcitabine (very low certainty).

• Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma 2021 · Cochrane Headline outcomes only
  RR 0.81 [0.58, 1.13]
  1 study · 70 participants
  Very low

Intervention not reported

• Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma 2015 · Cochrane Headline outcomes only
  no estimate extracted
  185 participants
  Low

Hepatic resection vs radiofrequency ablation

• Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma 2013 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 578 participants
  Moderate

Percutaneous ethanol injection vs radiofrequency ablation

• Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma 2013 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 1088 participants
  Moderate

Pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care vs best supportive care

It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes overall survival (absolute effect size estimates based on survival… compared with best supportive care alone (very low certainty).

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  HR 1.19 [0.78, 1.82]
  1 study · 129 participants
  Very low